Patents by Inventor Irene Waizenegger

Irene Waizenegger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical Combinations for Treating Cancer
    Publication number: 20240165169
    Abstract: The present invention relates to a pharmaceutical combination comprising a recombinant Gram-negative bacterial strain and an immune checkpoint modulator (ICM) and their use in a method for the prevention, delay of progression or treatment of cancer in a subject.
    Type: Application
    Filed: March 24, 2022
    Publication date: May 23, 2024
    Inventors: Simon ITTIG, Christoph KASPER, Falk SAUPE, Marlise AMSTUTZ, Mélodie DUVAL, Irene WAIZENEGGER
  • Chemical compounds
    Patent number: 8889665
    Abstract: The present invention encompasses compounds of general formula (1), wherein the groups R1 to R3 and L are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: July 1, 2008
    Date of Patent: November 18, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ioannis Sapountzis, Peter Ettmayer, Christian Klein, Andreas Mantoulidis, Steffen Steurer, Irene Waizenegger
  • ANTICANCER THERAPY
    Publication number: 20140194442
    Abstract: The invention describes anti-cancer therapies comprising using dual Aurora kinase/MEK inhibitors as described herein.
    Type: Application
    Filed: January 12, 2012
    Publication date: July 10, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Flavio Solca, Ulrich Guertler, Michael Sanderson, Ulrike Tontsch-Grunt, Irene Waizenegger
  • Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors
    Patent number: 8653087
    Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, X1, X2, X3, L1 and L2 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or anomalous cell proliferation, and the use thereof in such a treatment.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: February 18, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Mantoulidis, Georg Dahmann, Peter Ettmayer, Christian Klein, Steffen Steurer, Irene Waizenegger, Stephan Karl Zahn
  • Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof
    Patent number: 8404674
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1, R2 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Grant
    Filed: March 4, 2008
    Date of Patent: March 26, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Heinz Stadtmueller, Guido Boehmelt, Harald Engelhardt, Ulrich Hirt, Otmar Schaaf, Irene Waizenegger
  • ANTICANCER THERAPY
    Publication number: 20130004481
    Abstract: The invention describes anti-cancer therapies comprising using dual Aurora kinase/MEK inhibitors as described herein.
    Type: Application
    Filed: January 5, 2012
    Publication date: January 3, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Flavio Solca, Ulrich Guertler, Michael Sanderson, Ulrike Tontsch-Grunt, Irene Waizenegger
  • 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
    Patent number: 8258129
    Abstract: The present invention encompasses compounds of general formula (1) wherein X and R1 to R3 are as defined in the disclosure, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: September 4, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Gerd Bader, Guido Boehmelt, Ralph Brueckner, Thomas Gerstberger, Maria Impagnatiello, Daniel Kuhn, Otmar Schaaf, Heinz Stadtmueller, Irene Waizenegger, Andreas Zoephel
  • Thiazolyl-dihydro-indazoles
    Patent number: 8207349
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: June 26, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bodo Betzemeier, Trixi Brandl, Steffen Breitfelder, Ralph Brueckner, Thomas Gerstberger, Michael Gmachl, Matthias Grauert, Frank Hilberg, Christoph Hoenke, Matthias Hoffmann, Maria Impagnatiello, Dirk Kessler, Christian Klein, Bernd Krist, Udo Maier, Darryl McConnell, Charlotte Reither, Stefan Scheuerer, Andreas Schoop, Norbert Schweifer, Oliver Simon, Martin Steegmaier, Steffen Steurer, Irene Waizenegger, Ulrike Weyer-Czernilofsky, Andreas Zoephel
  • PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS
    Publication number: 20120094975
    Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, X1, X1, X3, L1 and L2 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell pro-liferation, and the use thereof in such a treatment.
    Type: Application
    Filed: September 8, 2009
    Publication date: April 19, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Andreas Mantoulidis, Georg Dahmann, Peter Ettmayer, Christian Klein, Steffen Steurer, Irene Waizenegger, Stephan Karl Zahn
  • NEW CHEMICAL COMPOUNDS
    Publication number: 20110183952
    Abstract: The present invention encompasses compounds of general formula (1), wherein the groups R1 to R3 and L are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: July 1, 2008
    Publication date: July 28, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Ioannis Sapountzis, Peter Ettmayer, Christian Klein, Andreas Mantoulidis, Steffen Steurer, Irene Waizenegger
  • COMPOUNDS
    Publication number: 20100311721
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1, R2 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: March 4, 2008
    Publication date: December 9, 2010
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Heinz Stadtmueller, Guido Boehmelt, Harald Engelhardt, Ulrich Hirt, Otmar Schaaf, Irene Waizenegger
  • CHEMICAL COMPOUNDS
    Publication number: 20100240657
    Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R2 to R4, L, Q and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition with the above-mentioned properties.
    Type: Application
    Filed: July 1, 2008
    Publication date: September 23, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Ioannis Sapountzis, Peter Ettmayer, Christian Klein, Andreas Mantoulidis, Martin Steegmaier, Steffen Steurer, Irene Waizenegger
  • THIAZOLYL-DIHYDRO-INDAZOLES
    Publication number: 20100113414
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Application
    Filed: January 11, 2010
    Publication date: May 6, 2010
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Bodo BETZEMEIER, Trixi BRANDL, Steffen BREITFELDER, Ralph BRUECKNER, Thomas GERSTBERGER, Michael GMACHL, Matthias GRAUERT, Frank HILBERG, Christoph HOENKE, Matthias HOFFMANN, Maria IMPAGNATIELLO, Dirk KESSLER, Christian KLEIN, Bernd KRIST, Udo MAIER, Darryl McCONNELL, Charlotte REITHER, Stefan SCHEUERER, Andreas SCHOOP, Norbert SCHWEIFER, Oliver SIMON, Martin STEEGMAIER, Steffen STEURER, Irene WAIZENEGGER, Ulrike WEYER-CZERNILOFSKY, Andreas ZOEPHEL
  • Thiazolyl-dihydro-indazole
    Patent number: 7691888
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Grant
    Filed: October 5, 2005
    Date of Patent: April 6, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bodo Betzemeier, Trixi Brandl, Steffen Breitfelder, Ralph Brueckner, Thomas Gerstberger, Michael Gmachl, Matthias Grauert, Frank Hilberg, Christoph Hoenke, Matthias Hoffmann, Maria Impagnatiello, Dirk Kessler, Christian Klein, Bernd Krist, Udo Maier, Darryl McConnell, Charlotte Reither, Stefan Scheuerer, Andreas Schoop, Norbert Schweifer, Oliver Simon, Martin Steegmaier, Steffen Steurer, Irene Waizenegger, Ulrike Weyer-Czernilofsky, Andreas Zoephel
  • 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS
    Publication number: 20090203673
    Abstract: The present invention encompasses compounds of general Formula (I) wherein X and R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: July 5, 2007
    Publication date: August 13, 2009
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Harald Engelhardt, Gerd Bader, Guido Boehmelt, Ralph Brueckner, Thomas Gerstberger, Maria Impagnatiello, Daniel Kuhn, Otmar Schaaf, Heinz Stadtmueller, Irene Waizenegger, Andreas Zoephel
  • Compounds modulating sister chromatid separation and method for identifying same
    Patent number: 7410774
    Abstract: Method for identifying compounds that interfere with or modulate sister chromatid separation in animal or plant cells by modulating a protease with separin-like cysteine endopeptidase activity. Inhibitors of separin activity are useful in cancer therapy, to prevent birth defects and to increase ploidy in plants.
    Type: Grant
    Filed: February 15, 2000
    Date of Patent: August 12, 2008
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Frank Uhlmann, Kim Nasmyth, Jan-Michael Peters, Irene Waizenegger, Sara Buonomo, Rosemary Clyne
  • Thiazolyl-dihydro-indazole
    Publication number: 20060100254
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in Claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Application
    Filed: October 5, 2005
    Publication date: May 11, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Bodo Betzemeier, Trixi Brandl, Steffen Breitfelder, Ralph Brueckner, Thomas Gerstberger, Michael Gmachl, Matthias Grauert, Frank Hilberg, Christoph Hoenke, Matthias Hoffmann, Maria Impagnatiello, Dirk Kessler, Christian Klein, Bernd Krist, Udo Maier, Darryl McConnell, Charlotte Reither, Stefan Scheuerer, Andreas Schoop, Norbert Schweifer, Oliver Simon, Martin Steegmaier, Steffen Steurer, Irene Waizenegger, Ulrike Weyer-Czernilofsky, Andreas Zoephel
  • Method for identifying compounds modulating sister chromatid separation
    Publication number: 20020164620
    Abstract: Screening methods for identifying separase inhibitors based on active forms of separase and compounds identified in such methods.
    Type: Application
    Filed: January 22, 2002
    Publication date: November 7, 2002
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Jan-Michael Peters, Irene Waizenegger, Wolfgang Sommergruber